This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering
Antibody Engineering

On-Demand Webcast: IgM Antibodies and Other Alternative Frameworks — Promise and Progress

Posted by on 31 May 2023
Share this article

In April, Informa Connect Life Sciences hosted a webcast with IGM Biosciences. It is now available to view on demand: Watch Now.

Janice Reichert, PhD
, Chief Operating Officer of The Antibody Society

William (Bill) Strohl, PhD, President, BiStro Biotech Consulting LLC
Bruce Keyt, PhD, Chief Scientific Officer at IGM Biosciences

Scientific innovations and advancements in antibody-based therapies, including alternative approaches using IgE, IgA, and IgM antibodies, are paving the way towards a new era of antibody medicines. Further development of new approaches beyond traditional IgG based efforts, may allow more patients with serious diseases to benefit. Early efforts to utilize these antibodies, with a focus on IgM, were challenging but significant progress has been made recently which highlights their potential as new therapeutic platforms.

IgM antibodies have a unique structure that addresses many of the limitations of traditional bivalent IgG antibodies. With 10 binding sites and a J-chain that can interact with different receptors, engineered IgM antibodies represent a new class of potential therapeutics that combine multivalency, high avidity, and high specificity.

These attributes have enabled the development of IgM antibodies that can more effectively bind and cluster receptors for induction of apoptosis, including IgM agonist of death receptor 5 (DR5), and bispecific T-cell engagers for treatment of solid and hematologic cancers, autoimmune/inflammatory diseases, and infectious diseases.

This webinar discusses the unique attributes of these antibodies and the potential applications of this approach to address unmet needs and create new opportunities for patients.

Key Topics:

  • Discuss the use of larger, alternative isotypes including IgE, IgA, and IgM as therapeutic antibody candidate scaffolds,
  • Discuss advancements in IgM antibody development and history of engineering and therapeutic efforts,
  • Review new approaches to agonist cell signaling and bispecific binding of disease-specific targets with engagement of T cells, and
  • Present exciting clinical results that bring promise to realizing therapeutic potential of engineered IgM antibodies.

By engaging with the audience, the speakers tackled some thought-provoking themes and challenges in the field of IgM-based therapies.

You can watch the complimentary recorded webcast now, on-demand.

Share this article